Efficiency and Safety of High-frequency Radio Wave Electrotherapy With a Radio Frequency of 448 kHz in the Treatment of Patients With Organic Erectile Dysfunction.

Overview

Efficiency and safety of high-frequency radio wave electrotherapy with a radio frequency of 448 kHz in the treatment of patients with organic erectile dysfunction. Sham comparator, parallel study including both the main and control group to demonstrate the efficiency of the device to treat erectile dysfunction.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: December 31, 2021

Detailed Description

The objectives of this study are: – To evaluate the effectiveness of the course treatment with the apparatus for continuous capacitive resistive monopolar electrotherapy with a radio frequency of 448 kHz in patients with organic erectile dysfunction. – Assess the safety and tolerability of continuous capacitive resistive monopolar electrotherapy with a radio frequency of 448 kHz in patients with organic erectile dysfunction. – To evaluate the duration of the effect of continuous capacitive resistive monopolar electrotherapy with a radio frequency of 448 kHz.

Interventions

  • Device: high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.
    • Patient in lithotomy position (supine) with return plate at lumbar level. Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient’s body. Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all).
  • Device: high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.
    • Doctor uses sham sensor to reduce efficiency to zero.

Arms, Groups and Cohorts

  • Experimental: Intervention group
  • Sham Comparator: Control group

Clinical Trial Outcome Measures

Primary Measures

  • A statistically significant increase in the number of points IIEF-5
    • Time Frame: Through study completion, an average of 3 months after first procedure
    • IIEF-5

Secondary Measures

  • A statistically significant increase in penile blood flow.
    • Time Frame: Through study completion, an average of 3 months after first procedure
    • According to Doppler
  • Statistically significant increase in SEP scores (Sexual Encounter Profile)
    • Time Frame: Through study completion, an average of 3 months after first procedure
    • Schramek grading system score for assessing penile rigidity

Participating in This Clinical Trial

Inclusion Criteria

1. Patients aged 18 to 79 years; 2. The diagnosis is confirmed by assessing the functional criteria of arterial factors of panel hemodynamics (dopplerography); 3. The diagnosis is confirmed by the assessment of the IIEF-5 questionnaire 4. Patients with organic erectile dysfunction lasting at least 6 months. 5. Patients with IIEF from 6 to 22 points. 6. Patients with a permanent sexual partner for more than 3 months; 7. Sexually Active Patients. Noninclusion criteria:

1. The use of other treatments for erectile dysfunction 2. Age under 18 and over 79 years old; 3. Anatomical deformation of the penis (angulation, cavernous fibrosis or Peyronie's disease); 4. The presence of diseases predisposing to the development of priapism (sickle cell anemia, multiple myeloma, leukemia, thrombocytopenia); 5. Running coagulation disorders; 6. The presence of tumors in the area of electrotherapy; 7. The presence of aneurysms in the propagation of radio frequency waves; 8. Angina pectoris; 9. Myocardial infarction, stroke, life-threatening arrhythmias; 10. Thrombosis, thromboembolic disease; 11. Arterial hypertension (blood pressure ≥ 170/90 mm Hg) or hypotension (blood pressure ≤ 90/50 mm Hg.); 12. The patient has a mental illness that does not allow an assessment of the effectiveness of therapy; history of alcoholism and drug addiction; 14. Active tuberculosis, chronic somatic diseases in the acute stage; 15. Condition after coronary artery bypass grafting (CABG); 16. Patient's involvement in another clinical trial in the last 3 months; Exclusion Criteria:

1. Serious unwanted phenomenons associated with exposure to the apparatus. 2. Incorrect inclusion in the study. 3. A marked deterioration in the patient's condition due to an increase in the severity of the disease or the attachment of another disease. 4. The patient's appearance of noninclusion criteria during the study. 5. Serious deviation from the protocol. 6. The desire of the patient or his legal representative.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • I.M. Sechenov First Moscow State Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dmitry Enikeev, MD, PhD, Director for Research – I.M. Sechenov First Moscow State Medical University
  • Overall Official(s)
    • Dmitry Korolev, M.D., Principal Investigator, Sechenov University
  • Overall Contact(s)
    • Dmitry Enikeev, M.D., Ph.D., 89267677873, dvenikeev@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.